Introduction Rituximab is a potent immunosuppressant used to treat haematological malignancies, rheumatological diseases and autoimmune disorders. Patients with current or past infection with the hepatitis B virus (HBV) are at high risk of reactivation following treatment with rituximab and other immunosuppressants.1HBV reactivation can cause liver failure and is associated with a 5–12% mortality. Guidelines advise screening for HBV surface antigen (HBsAg) and core antibody (anti-HBcAb) prior to initiating immunosuppression, and recommend antiviral prophylaxis for all found to be positive.2
Method A baseline audit was conducted on all patients receiving rituximab in our Trust between Sept-Dec 2012 to determine the proportion of patients tested for HBsAg and anti-HBcAb. Data was also collected on prophylactic antiviral prescriptions. Following the baseline audit, a hospital guideline was developed and targeted education was conducted for rituximab prescribers. Two follow-up audits were conducted in Feb–April 2014 and Sept–Dec 2014.
Results A summary of the baseline results and follow-up audits is shown in Table 1. The baseline audit showed very low rates of HBV testing; only 23% tested for HBsAg and 19% for anti-HBcAb. None were HBsAg positive, but 2 were anti-HBcAb positive and neither received antiviral prophylaxis. One of these patients experienced HBV reactivation and despite tenofovir treatment developed liver failure requiring a 3-week hospital admission. The rituximab prescriptions were mainly from our rheumatology (56%) and haematology (32%) departments. This audit highlighted the need for education of clinicians prescribing rituximab. A Trust protocol was introduced and targeted education sessions were delivered to the specialties using rituximab. A significant stepwise increase in HBV testing was seen in follow-up audits (Table 1). By Sept-Dec 2014, 79% of patients were tested for HBsAg.
Conclusion In our Trust, introduction of a protocol and targeted education of clinicians has led to a dramatic increase in HBV screening prior to receiving rituximab (19% to 79%). However, reinforcement of the guidelines is needed to further increase testing rates and appropriate hepatology referrals. Importantly, prophylactic antiviral treatment was indicated for 5% of patients tested.
Disclosure of interest None Declared.
EASL Guidelines: Management of chronic HBV infection. J Hepatol. 2012;57:167–185
NICE Hepatitis B guidelines, 2013
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.